Everolimus and sirolimus in transplantation-related but different
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The inhibitors of the mammalian target of rapamycin (mTOR) sirolimus and everolimus are used not only as immunosuppressants after organ transplantation in combination with calcineurin inhibitors (CNIs) but also as proliferation signal inhibitors coated on drug-eluting stents and in cancer therapy. Notwithstanding their related chemical structures, both have distinct pharmacokinetic, pharmacodynamic and toxicodynamic properties. AREAS COVERED: The additional hydroxyethyl group at the C(40) of the everolimus molecule results in different tissue and subcellular distribution, different affinities to active drug transporters and drug-metabolizing enzymes as well as differences in drug-target protein interactions including a much higher potency in terms of interacting with the mTOR complex 2 than sirolimus. Said mechanistic differences as well as differences found in clinical trials in transplant patients are reviewed. EXPERT OPINION: In comparison to sirolimus, everolimus has higher bioavailability, a shorter terminal half-life, different blood metabolite patterns, the potential to antagonize the negative effects of CNIs on neuronal and kidney cell metabolism (which sirolimus enhances), the ability to stimulate mitochondrial oxidation (which sirolimus inhibits) and to reduce vascular inflammation to a greater extent. A head-to-head, randomized trial comparing the safety and tolerability of these two mTOR inhibitors in solid organ transplant recipients is merited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · cited 2×
“For more details and explanation of the acronyms, please see [21].”
BackgroundSummary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Growing roles for the mTOR pathway
Sarbassov, D. D., Ali, S. M., & Sabatini, D. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.009 · Cited by 1,560 · cited 1×
“This interrupts the mTOR intracellular signaling pathway, which is pivotal to multiple processes including, but not limited to, cell growth and proliferation, cellular metabolism and angiogenesis [15-21].”
BackgroundChemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands
Schreiber, S. L. (1991) · Science · doi:10.1126/science.1702904 · Cited by 1,494 · cited 3×
“Functionally, an FK-binding domain and an mTOR-binding domain have been identified (Figure 1) [25].”
BackgroundInfluentialEisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198 · cited 1×
“In this context, it is interesting to note that using an exposure-effect modeling approach based on the data from a 12-month Phase III clinical trial in heart transplant recipients [62], Starling et al.”
MethodChung, J., Kuo, C. J., Crabtree, G. R., & Blenis, J. (1992) · Cell · doi:10.1016/0092-8674(92)90643-q · Cited by 1,150
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989 · cited 1×
“In addition, mTOR inhibitors are used as proliferation signal inhibitors in cancer therapy [7,8] and coated on drug-eluting stents [9,10].”
BackgroundKahan, B. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02480-6 · Cited by 913
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo
Schuler, W., Sedrani, R., Cottens, S., H??berlin, B., Schulz, M., Schuurman, H.-J., Zenke, G., Zerwes, H.-G., & Schreier, M. H. (1997) · Transplantation · doi:10.1097/00007890-199707150-00008 · Cited by 533 · cited 6×
“Everolimus is a second-generation sirolimus derivative specifically developed to have improved pharmacokinetic properties including, but not limited to, facilitated oral formulation, higher oral bioavailability and better metabolic stability in comparison to sirolimus [13,17].”
BackgroundResultInfluentialClinical Pharmacokinetics of Everolimus
Kirchner, G. I., Meier-Wiedenbach, I., & Manns, M. P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443020-00002 · Cited by 508 · cited 5×
“Clinically, the longer elimination half-life of sirolimus has led to recommendations that a loading dose of three times the maintenance dose be administrated to achieve steady-state concentrations within 1 day in most patients [26,27].”
BackgroundInfluential
Cited by
Lutz, M., & Mielke, S. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13022 · Cited by 32
Metadata
- Authors
- Klawitter, J., Nashan, B., & Christians, U.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2015-04-26
- Volume
- 14
- Issue
- 7
- Pages
- 1055-1070
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2099073545
- Cited by
- 187
- References
- 81
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Everolimus and sirolimus in transplantation-related but different. https://app.cochat.ai/papers/10.1517/14740338.2015.1040388
- The paper
- Klawitter, J., Nashan, B., & Christians, U. (2015). Everolimus and sirolimus in transplantation-related but different. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.2015.1040388
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.